title: Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer.
abstract: In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.
authors.affiliation: Department of Oncology Ona, Finsen Institute, Copenhagen, Denmark.
authors.forename: A
authors.initials: A
authors.lastname: Krarup-Hansen
authors.forename: E
authors.initials: E
authors.lastname: Andersen
authors.forename: K
authors.initials: K
authors.lastname: Elbaek
authors.forename: S N
authors.initials: SN
authors.lastname: Rasmussen
authors.forename: M
authors.initials: M
authors.lastname: Dalmark
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D015255:Idarubicin